Sensyne Health plc announced that it has signed a five year non-exclusive Strategic Research Agreement (SRA) with Great Ormond Street Hospital for Children NHS Foundation Trust to analyse anonymised patient data using clinical artificial intelligence (Clinical AI) technology. The purpose of the SRA is to enable the ethical application of Clinical AI research to improve paediatric clinical outcomes, and accelerate research into new medicines to find new and better ways to treat rare and complex childhood diseases. The SRA is Sensyne's first to focus on improving care and accelerating the development of medicines specifically for children. The first project will focus on developing a clinical decision support algorithm to help clinicians caring for children with chronic kidney disease. This will then be used to develop further clinical support algorithms for other diseases in children. Development of paediatric medicines, from discovery through clinical development, has long been especially challenging. Recent developments in Clinical AI and the use of real world data provide an opportunity to develop new medicines and to accelerate the clinical development of treatments for childhood illnesses. This will be a key focus of the research that Sensyne and GOSH will seek to develop.